Acucela's Pipeline
Acucela is developing orally-delivered visual cycle modulation (VCM) therapies that selectively target cells within the retina to protect visual acuity and have the potential to treat blinding eye diseases that affect tens of millions people.
Although our primary focus is on developing safe and effective treatments for age-related macular degeneration (AMD), we also have programs underway to treat other potentially devastating ophthalmic diseases and disorders, including retinopathy of prematurity, Stargardt disease, diabetic retinopathy and dry eye syndrome.
